Xuechong Hong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xuechong Hong has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Juan M. Melero-Martin
Department of Cardiac Surgery, Boston Children’s Hospital, Boston, USA
5 shared publications Joseph Neumeyer
Department of Cardiac Surgery, Boston Children’s Hospital, Boston, USA
3 shared publications- Kai Wang
Department of Physiology and Pathophysiology, School of Basic Medical Sciences, State Key Laboratory of Vascular Homeostasis and Remodeling, Beijing Advanced Center of Cellular Homeostasis and Aging-Related Diseases, Clinical Stem Cell Research Center, Peking University Third Hospital, Peking University, Beijing, China
3 shared publications - Ruei-Zeng Lin
Department of Cardiac Surgery, Children's Hospital Boston, and Harvard Medical School, Boston, MA
3 shared publications Chin Nien Lee
Department of Cardiac Surgery, Boston Children’s Hospital, Boston, USA
2 shared publications- Xi Wang
Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Clinical Stem Cell Research Center, Peking University Third Hospital, Beijing Advanced Center of Cellular Homeostasis and Aging-Related Diseases, Peking University, Beijing, China
2 shared publications
Latest Publications
- Open Access
- 22 July 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (29) , eabn0071
Engineered immunomodulatory accessory cells improve experimental allogeneic islet transplantation without immunosuppression
Islet transplantation has been established as a viable treatment modality for type 1 diabetes. However, the side effects of the systemic immunosuppression required for patients often outweigh its benefits. Here, we engineer programmed death ligand-1 and cytotoxic T lymphocyte antigen 4 immunoglobulin fusion protein–modified mesenchymal stromal cells (MSCs) as accessory cells for islet cotransplantation. The engineered MSCs (eMSCs) improved the outcome of both syngeneic and allogeneic islet transplantation in diabetic mice and resulted in allograft survival for up to 100 days without any systemic immunosuppression. Immunophenotyping revealed reduced infiltration of CD4 + or CD8 + T effector cells and increased infiltration of T regulatory cells within the allografts cotransplanted with eMSCs compared to controls. The results suggest that the eMSCs can induce local immunomodulation and may be applicable in clinical islet transplantation to reduce or minimize the need of systemic immunosuppression and ameliorate its negative impact.
- 22 July 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (29) , eabn0071
Open AccessEngineered immunomodulatory accessory cells improve experimental allogeneic islet transplantation without immunosuppression
Islet transplantation has been established as a viable treatment modality for type 1 diabetes. However, the side effects of the systemic immunosuppression required for patients often outweigh its benefits. Here, we engineer programmed death ligand-1 and cytotoxic T lymphocyte antigen 4 immunoglobulin fusion protein–modified mesenchymal stromal cells (MSCs) as accessory cells for islet cotransplantation. The engineered MSCs (eMSCs) improved the outcome of both syngeneic and allogeneic islet transplantation in diabetic mice and resulted in allograft survival for up to 100 days without any systemic immunosuppression. Immunophenotyping revealed reduced infiltration of CD4 + or CD8 + T effector cells and increased infiltration of T regulatory cells within the allografts cotransplanted with eMSCs compared to controls. The results suggest that the eMSCs can induce local immunomodulation and may be applicable in clinical islet transplantation to reduce or minimize the need of systemic immunosuppression and ameliorate its negative impact.
- Open Access
- 9 July 2021
- Published by Wiley in Advanced Healthcare Materials
- Vol. 10 (13) , 2170060
Bone Tissue Engineering: A Biphasic Osteovascular Biomimetic Scaffold for Rapid and Self‐Sustained Endochondral Ossification (Adv. Healthcare Mater. 13/2021)
- 9 July 2021
- Published by Wiley in Advanced Healthcare Materials
- Vol. 10 (13) , 2170060
Open AccessBone Tissue Engineering: A Biphasic Osteovascular Biomimetic Scaffold for Rapid and Self‐Sustained Endochondral Ossification (Adv. Healthcare Mater. 13/2021)
- 17 January 2021
- Published by Springer Nature in Angiogenesis
- Vol. 24 (2) , 327-344
Human endothelial colony-forming cells provide trophic support for pluripotent stem cell-derived cardiomyocytes via distinctively high expression of neuregulin-1
The search for a source of endothelial cells (ECs) with translational therapeutic potential remains crucial in regenerative medicine. Human blood-derived endothelial colony-forming cells (ECFCs) represent a promising source of autologous ECs due to their robust capacity to form vascular networks in vivo and their easy accessibility from peripheral blood. However, whether ECFCs have distinct characteristics with translational value compared to other ECs remains unclear. Here, we show that vascular networks generated with human ECFCs exhibited robust paracrine support for human pluripotent stem cell-derived cardiomyocytes (iCMs), significantly improving protection against drug-induced cardiac injury and enhancing engraftment at ectopic (subcutaneous) and orthotopic (cardiac) sites. In contrast, iCM support was notably absent in grafts with vessels lined by mature-ECs. This differential trophic ability was due to a unique high constitutive expression of the cardioprotective growth factor neuregulin-1 (NRG1). ECFCs, but not mature-ECs, were capable of actively releasing NRG1, which, in turn, reduced apoptosis and increased the proliferation of iCMs via the PI3K/Akt signaling pathway. Transcriptional silencing of NRG1 abrogated these cardioprotective effects. Our study suggests that ECFCs are uniquely suited to support human iCMs, making these progenitor cells ideal for cardiovascular regenerative medicine.
- 17 January 2021
- Published by Springer Nature in Angiogenesis
- Vol. 24 (2) , 327-344
Human endothelial colony-forming cells provide trophic support for pluripotent stem cell-derived cardiomyocytes via distinctively high expression of neuregulin-1
The search for a source of endothelial cells (ECs) with translational therapeutic potential remains crucial in regenerative medicine. Human blood-derived endothelial colony-forming cells (ECFCs) represent a promising source of autologous ECs due to their robust capacity to form vascular networks in vivo and their easy accessibility from peripheral blood. However, whether ECFCs have distinct characteristics with translational value compared to other ECs remains unclear. Here, we show that vascular networks generated with human ECFCs exhibited robust paracrine support for human pluripotent stem cell-derived cardiomyocytes (iCMs), significantly improving protection against drug-induced cardiac injury and enhancing engraftment at ectopic (subcutaneous) and orthotopic (cardiac) sites. In contrast, iCM support was notably absent in grafts with vessels lined by mature-ECs. This differential trophic ability was due to a unique high constitutive expression of the cardioprotective growth factor neuregulin-1 (NRG1). ECFCs, but not mature-ECs, were capable of actively releasing NRG1, which, in turn, reduced apoptosis and increased the proliferation of iCMs via the PI3K/Akt signaling pathway. Transcriptional silencing of NRG1 abrogated these cardioprotective effects. Our study suggests that ECFCs are uniquely suited to support human iCMs, making these progenitor cells ideal for cardiovascular regenerative medicine.
- Open Access
- 24 July 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (30) , eaba7606
Robust differentiation of human pluripotent stem cells into endothelial cells via temporal modulation of ETV2 with modified mRNA
Human induced pluripotent stem cell (h-iPSC)–derived endothelial cells (h-iECs) have become a valuable tool in regenerative medicine. However, current differentiation protocols remain inefficient and lack reliability. Here, we describe a method for rapid, consistent, and highly efficient generation of h-iECs. The protocol entails the delivery of modified mRNA encoding the transcription factor ETV2 at the intermediate mesodermal stage of differentiation. This approach reproducibly differentiated 13 diverse h-iPSC lines into h-iECs with exceedingly high efficiency. In contrast, standard differentiation methods that relied on endogenous ETV2 were inefficient and notably inconsistent. Our h-iECs were functionally competent in many respects, including the ability to form perfused vascular networks in vivo. Timely activation of ETV2 was critical, and bypassing the mesodermal stage produced putative h-iECs with reduced expansion potential and inability to form functional vessels. Our protocol has broad applications and could reliably provide an unlimited number of h-iECs for vascular therapies.
- 24 July 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (30) , eaba7606
Open AccessRobust differentiation of human pluripotent stem cells into endothelial cells via temporal modulation of ETV2 with modified mRNA
Human induced pluripotent stem cell (h-iPSC)–derived endothelial cells (h-iECs) have become a valuable tool in regenerative medicine. However, current differentiation protocols remain inefficient and lack reliability. Here, we describe a method for rapid, consistent, and highly efficient generation of h-iECs. The protocol entails the delivery of modified mRNA encoding the transcription factor ETV2 at the intermediate mesodermal stage of differentiation. This approach reproducibly differentiated 13 diverse h-iPSC lines into h-iECs with exceedingly high efficiency. In contrast, standard differentiation methods that relied on endogenous ETV2 were inefficient and notably inconsistent. Our h-iECs were functionally competent in many respects, including the ability to form perfused vascular networks in vivo. Timely activation of ETV2 was critical, and bypassing the mesodermal stage produced putative h-iECs with reduced expansion potential and inability to form functional vessels. Our protocol has broad applications and could reliably provide an unlimited number of h-iECs for vascular therapies.
- Open Access
- 18 December 2019
- Published by American Society of Hematology in Blood Advances
- Vol. 3 (24) , 4166-4176
Bioengineering hemophilia A–specific microvascular grafts for delivery of full-length factor VIII into the bloodstream
Key Points: HA-specific iPSC-derived ECs overexpress full-length F8 after genetic engineering via a piggyBac transposon system. Bioengineered microvascular grafts deliver full-length FVIII into the bloodstream and restore hemostasis in hemophilic SCID mice.
- 18 December 2019
- Published by American Society of Hematology in Blood Advances
- Vol. 3 (24) , 4166-4176
Open AccessBioengineering hemophilia A–specific microvascular grafts for delivery of full-length factor VIII into the bloodstream
Key Points: HA-specific iPSC-derived ECs overexpress full-length F8 after genetic engineering via a piggyBac transposon system. Bioengineered microvascular grafts deliver full-length FVIII into the bloodstream and restore hemostasis in hemophilic SCID mice.